A two arm phase II study of FOLFIRI in combination with standard or escalating dose of cetuximab as first line treatment for metastatic colorectal cancer: Everest 2 final results

Chiritescu, G., Dumon, K., Mercadé, T. M., Lang, I., Vivas, C. S., Papai, Z., Janssens, J., Hendrickx, K., Pracht, M., Van den Eynde, M., Taïeb, J., Moons, V., Geboes, K., Van Laethem, J., Greil, R., Cervantes, A., Vergauwe, P., Ferrante, M., Vanderstraeten, E., et al. (2018). A two arm phase II study of FOLFIRI in combination with standard or escalating dose of cetuximab as first line treatment for metastatic colorectal cancer: Everest 2 final results. Published. ESMO 20th World Congress on Gastrointestinal Cancer, (Spain) Barcelona. https://doi.org/10.1093/annonc/mdy149.014